Limits...
Sales of macrolides, lincosamides, streptogramins, and amoxicillin/clavulanate in the in- and outpatient setting in 10 European countries, 2007-2010.

Ferrer P, Sabaté M, Ballarín E, Fortuny J, Rottenkolber M, Schmiedl S, Laporte JR, Ibáñez L - Springerplus (2015)

Bottom Line: During the study period, the consumption of macrolides decreased, the consumption of AMC increased in most of European countries, and lincosamides varied very slightly.There was a wide inter-country variability in the percentage of the prescriptions assigned to each of the diagnostic categories.The inter-country differences in the consumption of these antibiotics and their prescription by diagnostic categories point to an inappropriate use of antibiotics.

View Article: PubMed Central - PubMed

Affiliation: Fundació Institut Català de Farmacologia, Pg Vall d'Hebron 119-129, 08029 Barcelona, Spain.

ABSTRACT
Monitoring the use of antibiotics is relevant due to the public health impact of microbial resistance, adverse effects, and costs. We present data on the consumption of macrolides, lincosamides, streptogramins and amoxicillin/clavulanate (AMC) between 2007 and 2010 in the in-and outpatient healthcare setting in 10 European countries provided by IMS Health. Antibiotics were classified according to the anatomical therapeutic chemical classification and consumption was expressed in defined daily doses/1000 inhabitants/day (DIDs). We analysed the number of prescriptions by diagnostic codes between 2008 and 2010, based on the International Classification of Diseases, 10th revision (ICD-10). These ICD-10 codes were grouped into four main categories: respiratory infections, genitourinary infections, other infections and other diagnoses. In 2010, the consumption of macrolides and lincosamides ranged from 0.45 DIDs (Sweden) to 5.46 DIDs (Italy), and from 0.04 DIDs (Denmark) to 1.00 DID (Germany), respectively. Streptogramins were available in France, Germany, Italy, Norway, Spain and United Kingdom with a consumption of <0.001 DID exclusively in the hospital setting. The consumption of AMC ranged from <0.001 DIDs (Norway) to 11.67 DIDs (Spain). During the study period, the consumption of macrolides decreased, the consumption of AMC increased in most of European countries, and lincosamides varied very slightly. Macrolides and AMC were mainly prescribed for respiratory infections in all countries but United Kingdom, where most of the prescriptions were assigned to diagnostic codes not clearly related with an infection. Lincosamides were prescribed for the respiratory infections and other infections groups. There was a wide inter-country variability in the percentage of the prescriptions assigned to each of the diagnostic categories. The inter-country differences in the consumption of these antibiotics and their prescription by diagnostic categories point to an inappropriate use of antibiotics.

No MeSH data available.


Related in: MedlinePlus

Prescription rates (×1000) of amoxicillin-clavulanate by diagnostic category and country, 2008–2010
© Copyright Policy - OpenAccess
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4628133&req=5

Fig4: Prescription rates (×1000) of amoxicillin-clavulanate by diagnostic category and country, 2008–2010

Mentions: For AMC, the pattern of use was similar to that of macrolides over the study period. All countries except the United Kingdom used AMC for respiratory infections, whereas in the United Kingdom 53.5 % of the AMC prescriptions were for other diagnoses. The percentage of use of AMC for respiratory infections ranged between 38.7 % in the Netherlands and 78.9 % in France. Bronchitis, tonsilitis and otitis media were the main indications for use. Figure 4 shows the prescription rates of AMC by diagnostic category and country, 2008–2010.Fig. 4


Sales of macrolides, lincosamides, streptogramins, and amoxicillin/clavulanate in the in- and outpatient setting in 10 European countries, 2007-2010.

Ferrer P, Sabaté M, Ballarín E, Fortuny J, Rottenkolber M, Schmiedl S, Laporte JR, Ibáñez L - Springerplus (2015)

Prescription rates (×1000) of amoxicillin-clavulanate by diagnostic category and country, 2008–2010
© Copyright Policy - OpenAccess
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4628133&req=5

Fig4: Prescription rates (×1000) of amoxicillin-clavulanate by diagnostic category and country, 2008–2010
Mentions: For AMC, the pattern of use was similar to that of macrolides over the study period. All countries except the United Kingdom used AMC for respiratory infections, whereas in the United Kingdom 53.5 % of the AMC prescriptions were for other diagnoses. The percentage of use of AMC for respiratory infections ranged between 38.7 % in the Netherlands and 78.9 % in France. Bronchitis, tonsilitis and otitis media were the main indications for use. Figure 4 shows the prescription rates of AMC by diagnostic category and country, 2008–2010.Fig. 4

Bottom Line: During the study period, the consumption of macrolides decreased, the consumption of AMC increased in most of European countries, and lincosamides varied very slightly.There was a wide inter-country variability in the percentage of the prescriptions assigned to each of the diagnostic categories.The inter-country differences in the consumption of these antibiotics and their prescription by diagnostic categories point to an inappropriate use of antibiotics.

View Article: PubMed Central - PubMed

Affiliation: Fundació Institut Català de Farmacologia, Pg Vall d'Hebron 119-129, 08029 Barcelona, Spain.

ABSTRACT
Monitoring the use of antibiotics is relevant due to the public health impact of microbial resistance, adverse effects, and costs. We present data on the consumption of macrolides, lincosamides, streptogramins and amoxicillin/clavulanate (AMC) between 2007 and 2010 in the in-and outpatient healthcare setting in 10 European countries provided by IMS Health. Antibiotics were classified according to the anatomical therapeutic chemical classification and consumption was expressed in defined daily doses/1000 inhabitants/day (DIDs). We analysed the number of prescriptions by diagnostic codes between 2008 and 2010, based on the International Classification of Diseases, 10th revision (ICD-10). These ICD-10 codes were grouped into four main categories: respiratory infections, genitourinary infections, other infections and other diagnoses. In 2010, the consumption of macrolides and lincosamides ranged from 0.45 DIDs (Sweden) to 5.46 DIDs (Italy), and from 0.04 DIDs (Denmark) to 1.00 DID (Germany), respectively. Streptogramins were available in France, Germany, Italy, Norway, Spain and United Kingdom with a consumption of <0.001 DID exclusively in the hospital setting. The consumption of AMC ranged from <0.001 DIDs (Norway) to 11.67 DIDs (Spain). During the study period, the consumption of macrolides decreased, the consumption of AMC increased in most of European countries, and lincosamides varied very slightly. Macrolides and AMC were mainly prescribed for respiratory infections in all countries but United Kingdom, where most of the prescriptions were assigned to diagnostic codes not clearly related with an infection. Lincosamides were prescribed for the respiratory infections and other infections groups. There was a wide inter-country variability in the percentage of the prescriptions assigned to each of the diagnostic categories. The inter-country differences in the consumption of these antibiotics and their prescription by diagnostic categories point to an inappropriate use of antibiotics.

No MeSH data available.


Related in: MedlinePlus